InvestorsHub Logo
Followers 69
Posts 6508
Boards Moderated 0
Alias Born 02/10/2010

Re: srinsocal post# 305158

Sunday, 01/01/2023 11:43:25 AM

Sunday, January 01, 2023 11:43:25 AM

Post# of 330578
NASA Ranks ActiPatch First in order of perceived ability to implement during spaceflight

"The treatment method ranked first in this review was pulsed
shortwave therapy (PSWT), a low-power RF (MHz range)
transmitter operated adjacent to biological tissue at maximum
output (saturation) to modulate peripheral nerve activity.
ActiPatch is a very small wearable PSWT device that is FDA
approved for “adjunctive treatment of musculoskeletal pain”
[Anwar-Deen 2020]. It is low cost, low power, and boasts 97%
efficacy in reducing pain (85% over a 6-month period) [Staelin
2019]. The device can be secured to the body by physio tape and
the area causing pain is bounded by the device’s ring. The device
can be turned on and off, and the non-rechargeable battery is capable of 720 hours of operation (one month continuous use). ActiPatch is sold OTC in local pharmacies for ~$30 [ActiPatch 2020]" page 15

https://ntrs.nasa.gov/api/citations/20205008893/downloads/2020ICA_Mullenax_report_24Sep20.pdf